News >

EU Panel Recommends Olaparib Tablets for Ovarian Cancer, Regardless of BRCA Status

Jason M. Broderick @jasoncology
Published: Friday, Feb 23, 2018

Sean Bohen, MD, PhD

Sean Bohen, MD, PhD
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of olaparib tablets (Lynparza) as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy, regardless of BRCA status.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Consultations® in Ovarian Cancer: Differentiating Among Clinical Trial Designs to Match PARP to PatientOct 31, 20191.5
Cancer Summaries and Commentaries™: Update from Munich: Advances in the Treatment of Lung Cancer, Genitourinary Malignancies, and Gynecologic MalignanciesDec 30, 20192.25
Publication Bottom Border
Border Publication